FDA Approves Xacduro (sulbactam and durlobactam) for the Treatment of Serious Infections Caused by Acinetobacter

WALTHAM, Mass.--(BUSINESS WIRE)--May 23, 2023-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved Xacduro® (sulbactam for injection;...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news